Drug Insights

Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach

6 February 2024
2 min read

Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain. It may be used together with rest, physical therapy, and pain medication. It is less preferred in low back pain. It has limited use for rheumatoid arthritis and cerebral palsy. Effects generally begin within half an hour. It is taken by mouth or injection into a vein. Common side effect include headaches, sleepiness, and dizziness. Serious side effects may include anaphylaxis, liver problems, confusion, and seizures. Use is not recommended in pregnancy and breastfeeding. Because of risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients. Methocarbamol is a centrally acting muscle relaxant. How it works is unclear, but it does not appear to affect muscles directly. Click on the image below to begin the exploration journey of Methocarbamol through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
Latest Hotspot
4 min read
U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
6 February 2024
Takeda has disclosed that GAMMAGARD LIQUID®, their intravenous immunoglobulin treatment, has received authorization from the U.S. Food and Drug Administration.
Read →
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
6 February 2024
Clindamycin was first made in 1966 from lincomycin and it is of the lincosamide class and works by blocking bacteria from making protein.
Read →
Alligator Bioscience Shows Promising Phase 2 Results from OPTIMIZE-1 Study Against Pancreatic Cancer
Latest Hotspot
3 min read
Alligator Bioscience Shows Promising Phase 2 Results from OPTIMIZE-1 Study Against Pancreatic Cancer
4 February 2024
Alligator Bioscience Reveals Encouraging Phase 2 Outcomes from OPTIMIZE-1 Study, Succeeding in Main Goal and Showing Significant Survival Advantages for Initial Treatment of Pancreatic Cancer.
Read →
Vidac Pharma Shares Promising Early Phase 2a Trial Results for Rare Skin Cancer Drug, VDA-1102
Latest Hotspot
3 min read
Vidac Pharma Shares Promising Early Phase 2a Trial Results for Rare Skin Cancer Drug, VDA-1102
4 February 2024
Vidac Pharma shares encouraging early results from a Phase 2a trial for a rare skin cancer, cutaneous T-cell lymphoma, using its primary drug candidate, VDA-1102.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.